First-line treatment with relatinib + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma
Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. In this MEDtalk Evan J Lipson presents a human IgG4 LAG-3-blocking antibody in combination with nivolumab form the RELATIVITY-047 study.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.